Business Context and Reporting Period
Tempus AI, Inc. (TEM) filed a Form 8-K on November 4, 2024, announcing the entry into a Material Definitive Agreement to acquire Ambry Genetics Corporation, a leader in genetic testing. The transaction is structured as a purchase of all outstanding shares of Ambry from REALM IDx, Inc. and its ultimate parent, Konica Minolta, Inc.
Key Financial Metrics and Transaction Structure
The filing details the consideration and financing for the acquisition but does not report standard operating metrics such as revenue, profit, or cash flow for the period.
- Total Consideration: Approximately $375.0 million in cash (subject to adjustments) plus 4,843,136 shares of Tempus AI Class A common stock.
- Cash Consideration Details: $5.0 million of the cash portion will be held in escrow for post-closing adjustments.
- Stock Consideration: 2,152,505 of the issued shares are subject to a one-year lock-up agreement.
- Financing Commitments: Ares Capital Corporation affiliates committed to provide a $100.0 million senior secured revolving credit facility and $200.0 million in additional term loans to fund the cash consideration and transaction expenses.
Material Changes and Outlook
This filing represents a material change in the company's strategic direction through a significant acquisition. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions including regulatory approvals (Hart-Scott-Rodino Act) and the accuracy of representations and warranties.
The agreement includes a termination right if the acquisition is not consummated by May 4, 2025, though this date may be extended by up to three months if delays are solely due to regulatory approvals.
Risks and Contingencies
- Regulatory Approval: Closing is contingent upon obtaining required regulatory approvals.
- Financing Conditions: While the company's obligation to close is not conditioned on financing, Ares' obligation to provide funds is subject to customary conditions, including the execution of definitive documentation.
- Forward-Looking Statements: The company cautions that the ability to consummate the deal and realize expected benefits is subject to substantial risks and uncertainties.
- Insurance: The company has obtained a buyside representation and warranty insurance policy to cover certain breaches.
Investor Verification Checklist
- Verify the final closing date and whether the May 4, 2025 termination deadline is extended.
- Confirm the receipt of all necessary regulatory approvals, specifically under the Hart-Scott-Rodino Act.
- Monitor the execution of definitive documentation required to release the $300.0 million in committed financing from Ares Capital Corporation.
- Review the final purchase price adjustments regarding cash, indebtedness, and net working capital of Ambry.
- Assess the impact of the 4,843,136 new shares of Class A common stock on existing shareholder dilution.